Promus PREMIER™ H7493925216250Recalls & reported problems
Boston Scientific Corporation · Everolimus-Eluting Platinum Chromium Coronary Stent System · Class 3 · Implant
All models of Promus PREMIER (56)
Data updated Oct 18, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 2
- Deaths reported
- 0
- Injuries reported
- 2
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 2 adverse event reports that list this exact device (DI 08714729828860), received between Jul 23, 2018 and Oct 12, 2023 — classified as 2 injuries.
The most frequently reported specific device problem is “Obstruction of Flow” (1 report).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Reports received per month
Most reported problems
Device problems
- Adverse Event Without Identified Device or Use Problem1
- Obstruction of Flow1
Patient problems
- Angina1
- Cardiac Arrest1
- High Blood Pressure/ Hypertension1
- Myocardial Infarction1
- Restenosis1
Recent adverse event reports
The 2 most recent of 2 reports, in the reporter's own words as published by the FDA.
InjuryOct 12, 2023Obstruction of Flow; Obstruction of Flow
IT WAS REPORTED THAT RESTENOSIS OCCURRED. ON (B)(6) 2018, THE PATIENT PRESENTED WITH UNSTABLE ANGINA. CORONARY ANGIOGRAPHY REVEALED A BIFURCATED MID LEFT ANTERIOR DESCENDING ARTERY (LAD) WITH 80-90% DISEASE. THE TARGET LESION WAS DIRECTLY STENTED WITH A 16 X 2.50 PROMUS PREMIER DRUG ELUTING STENT RESULTING IN 0% RESIDUAL STENOSIS. THE PATIENT WAS STABLE AND DISCHARGED ON DUAL ANTIPLATELET TREATMENT. ON (B)(6) 2023, THE PATIENT PRESENTED WITH UNSTABLE ANGINA, EXPERIENCING LEFT-SIDED CHEST PAIN RADIATING INTO THE LEFT SHOULDER AND DOWN THE LEFT ARM FOR 2 DAYS. HEPARIN DRIP WAS STARTED, AND THE PATIENT WAS STABLE, AND THEIR PAIN WAS RESOLVED. THE PATIENT WAS DIAGNOSED WITH NON-ST-ELEVATION MYOCARDIAL INFRACTION AND HYPERTENSION. VASCULAR ACCESS WAS OBTAINED VIA THE RIGHT FEMORAL ARTERY. ANGIOGRAPHY REVEALED 99% IN-STENT RESTENOSIS OF THE PREVIOUSLY DEPLOYED PROMUS PREMIER DRUG ELUTING STENT. FOLLOWING PRE-DILATION WITH A 2.00 X 12 EMERGE BALLOON, SUCCESSFUL ANGIOPLASTY WAS PERFORMED USING A 2.75 X 22 NON-BSC DRUG ELUTING STENT. FOLLOWING POST DILATION THERE WAS NO RESIDUAL STENOSIS. THE PATIENT BECAME SEVERELY NAUSEATED AND HYPERTENSIVE POSSIBLY DUE TO A CONTRAST ALLERGY AND WAS GIVEN
Patient problems: Angina; High Blood Pressure/ Hypertension; Myocardial Infarction; Restenosis
MAUDE report 17924951 ↗InjuryJul 23, 2018Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem
SAME CASE AS MDR ID: 2134265-2018-07108, 2134265-2018-07109, 2134265-2018-07110. IT WAS REPORTED THAT PATIENT ¿CODED¿. THE 90% STENOSED TARGET LESION WAS LOCATED IN THE LEFT ANTERIOR DESCENDING (LAD) ARTERY. THE PATIENT ALSO HAD A CHRONIC TOTAL OCCLUSION IN THE RIGHT LAD AS WELL AS SIGNIFICANT DISEASE IN THE CIRCUMFLEX AND IN THE OBTUSE MARGINALS. THERE WERE A TOTAL OF 4 BSC STENTS DEPLOYED IN THE LAD AND ONLY ONE WAS EXPIRED WHICH WAS THE 16 X 2.50 PROMUS PREMIER¿ STENT. THE 3 OTHER STENTS WERE ONE PROMUS OTW AND 2 SYNERGY MR STENTS. THE EXPIRED STENT WAS DISCOVERED AFTER THE CASE, WHEN THE DEVICES USED WERE BEING CONSOLIDATED. THE PROCEDURE WAS COMPLETED AND THE PATIENT WAS FINE. HOWEVER, 3 DAYS POST-PROCEDURE, THE PATIENT CODED. A TEMPORARY PACEMAKER WAS IMPLANTED TO CONTROL THE PATIENT'S HEART RHYTHM. NO FURTHER PATIENT COMPLICATIONS WERE REPORTED AND THE PATIENT WAS RECOVERING.
Patient problems: Cardiac Arrest
MAUDE report 7710617 ↗
Other Coronary drug-eluting stent devices
- SYNERGY™ H7493926038300Boston Scientific Corporation · Coronary drug-eluting stent8 deaths124 reports
- SYNERGY™ H7493926016300Boston Scientific Corporation · Coronary drug-eluting stent7 deaths106 reports
- SYNERGY™ H7493926020300Boston Scientific Corporation · Coronary drug-eluting stent9 deaths90 reports
- SYNERGY™ H7493926016250Boston Scientific Corporation · Coronary drug-eluting stent6 deaths82 reports
- XIENCE Sierra™ 1550350-33Abbott Vascular Inc. · Coronary drug-eluting stent1 recall32 reports
- Resolute Onyx™ RONYX30022UXMedtronic, Inc. · Coronary drug-eluting stent6 deaths76 reports
- SYNERGY™ H7493926024300Boston Scientific Corporation · Coronary drug-eluting stent3 deaths75 reports
- Resolute Onyx™ RONYX30015UXMedtronic, Inc. · Coronary drug-eluting stent3 deaths73 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page